Day One Biopharmaceuticals, Inc. (DAWN) Stock
DAWN has an Alpha Score of 17 out of 100 (poor), computed on Nov 7, 2026 from 1 of 4 sub-scores.
What is DAWN's Alpha Score?
How it works →Alpha Score of 17 reflects poor overall profile with weak quality. Based on 1 of 4 signals – score is capped at 50 until remaining data ingests.
Computed from 1 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are DAWN's key statistics?
Key statistics as of Nov 9, 2026
How does DAWN's valuation compare with the Healthcare sector?
| Metric | DAWN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -67.85% | 3.60% | 175 |
| Return on equity | -23.43% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
DAWN price chart
Powered by TradingViewWhat does Day One Biopharmaceuticals, Inc. do?
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the identification, development, and commercialization of targeted medicines for life-threatening childhood and adult diseases, particularly cancers, in the United States. Its lead product, OJEMDA (tovorafenib), is an oral, brain-penetrant type II RAF kinase inhibitor approved for pediatric patients with relapsed or refractory BRAF fusion or rearrangement-positive low-grade glioma (pLGG). The company advances tovorafenib in frontline settings through partnerships like with Ipsen for ex-U.S. rights. Day One Biopharmaceuticals, Inc. also develops DAY301, a PTK7-targeted antibody-drug conjugate for advanced solid tumors, and Emi-Le (emiltatug ledadotin), a B7-H4-targeted antibody-drug conjugate for breast, ovarian, endometrial cancers, and adenoid cystic carcinoma. These pipeline assets are in Phase 1 clinical trials. Founded in 2018 and headquartered in the United States, the company employs a 'search & development' strategy led by oncology experts to deliver first- or best-in-class therapies addressing unmet needs in pediatric and adult oncology.